$ENDP (Endo International plc)

$ENDP {{ '2015-11-05T14:45:36+0000' | timeago}} • Webcast

$ENDP's US Branded business delivered sales of $305MM, while US Generics business posted sales of $368MM contributing to YTD total growth of 32% vs. the prior year. International Pharmaceutical business is meeting the company's expectations and the strategic portfolio of this business is continuing.

$ENDP {{ '2017-08-28T11:57:14+0000' | timeago}} • Announcement

Pharma company $ENDP said its operating subsidiary Par Pharmaceutical has received final approval from the FDA for 'vigabatrin oral solution.' The company has started shipping of the medicine. The medicine, which is the generic version of Sabril, is the first and only generic version available.

$ENDP {{ '2017-08-07T20:54:40+0000' | timeago}} • Announcement

$ENDP agreed to resolve virtually all known U.S. mesh product liability claims. As part of its 2Q17 results, the company plans to lift its mesh product liability accrual by $775MM, which is expected to cover about 22,000 U.S. mesh claims, as well as all known international mesh product liability claims and other mesh-related matters.

$ENDP {{ '2017-08-07T20:53:22+0000' | timeago}} • Announcement

$ENDP agreed to resolve virtually all known U.S. mesh product liability claims and that it is engaged in discussions to resolve the known remaining U.S. claims at reasonable values. $ENDP will make installment payments beginning in 4Q17 and continuing through 4Q19.

$ENDP {{ '2017-07-21T14:56:21+0000' | timeago}} • Announcement

$ENDP said it will be ceasing operations and closing its manufacturing and distribution facilities in Huntsville, Alabama. The closure is expected to take place over the next 12 to 18 months. These restructuring actions are expected to reduce $ENDP's workforce by about 875 positions and to result in pre-tax restructuring charges of about $325MM.

$ENDP {{ '2017-07-06T17:01:40+0000' | timeago}} • Announcement

Following FDA's June 2017 withdrawal request, $ENDP has decided to voluntarily remove OPANA ER, a painkiller, from the market, to prevent its misuse.  As a result, $ENDP expects to incur a pre-tax impairment charge of approx $20MM in 2Q17. Reported net sales of OPANA ER were $158.9MM for FY16 and $35.7MM for 1Q17.

$ENDP {{ '2017-07-05T12:36:12+0000' | timeago}} • Announcement

$ENDP today announced it has entered into a definitive agreement to sell Mexico City-based Grupo Farmacéutico SOMAR to Advent International for approximately $124MM subject to customary adjustments for cash, debt and working capital.

$ENDP {{ '2017-07-03T18:36:53+0000' | timeago}} • Announcement

$ENDP completed the divestiture of its South African based operations, Litha Healthcare Group, to Acino Pharma AG. At closing, the company received approx. $100MM in cash and may receive up to an additional $11MM in contingent consideration.

$ENDP {{ '2017-05-09T14:06:41+0000' | timeago}} • Announcement

$ENDP now sees FY17 total revenues of $3.45-3.60Bil, generating a diluted GAAP loss from continuing operations of $0.80-0.50 per share. Adjusted EBITDA from continuing operations is estimated to be between $1.50Bil to $1.58Bil for the full year.

$ENDP {{ '2017-05-09T14:04:01+0000' | timeago}} • Announcement

$ENDP saw an 8% jump in revenues of $1.04Bil for 1Q17 but its net attributable loss widened to $173.8MM from last year's $133.9MM loss. Losses rose to $0.78 per diluted share from $0.60 a share, as reported loss from continuing operations bloated 86% to $165.4MM for the quarter.

$ENDP {{ '2017-04-10T18:18:21+0000' | timeago}} • Announcement

$ENDP said its subsidiaries Endo Designated Activity Co., Endo Finance LLC and Endo Finco Inc. (Issuers) plan to offer senior secured notes. $ENDP plans to use this proceeds, together with the proceeds of its new term loan facility and cash on hand, to repay all its outstanding loans and all other obligations under its existing credit facilities.

$ENDP {{ '2017-02-28T15:24:45+0000' | timeago}} • Webcast

With regards to the 2018 outlook, $ENDP said that it is focused on 2017 alone at this point. The company said that it will not be able to guide beyond 2017 because of the uncertainties in the business.

$ENDP {{ '2017-02-28T15:11:42+0000' | timeago}} • Webcast

$ENDP expects Litha Healthcare Group divestiture to close in 2Q17. About 53% of total enterprise revenue in 2017 is expected to be realized in 1H17. Gross margin percentage in 1Q17 to be broadly in line to slightly below 4Q16 with meaningful improvement during the course of the year. 1Q17 operating expenses are estimated to be largely in line with 4Q16.

$ENDP {{ '2017-02-28T15:03:42+0000' | timeago}} • Webcast

$ENDP's net loss was $3.3Bil in 4Q16, resulting from $3.5Bil goodwill and intangible asset impairment charges reported in the quarter. The company conducted its annual goodwill and in-process R&D impairment tests and tested several other intangible assets during the quarter.

$ENDP {{ '2017-02-28T14:57:15+0000' | timeago}} • Infographic

$ENDP Endo International Earnings AlphaGraphics: Q4 2016 Highlights

$ENDP {{ '2017-02-28T14:49:41+0000' | timeago}} • Webcast

In 2017, $ENDP expects US Branded Pharma segment revenue to decline in the low-to-mid teen percentage range year-over-year. Specialty business is expected to grow in the high-single digit.

$ENDP {{ '2017-02-28T14:34:19+0000' | timeago}} • Webcast

For 2017, $ENDP expects US Generics base business revenue decline to be similar to 2016 or in the low 30% range. Generics segment sales are expected to decline in the high-single to low-double digit range. In US Generics business, $ENDP estimates to realize approx. $75MM in annual net savings and launch at least 20 products in 2017.

$ENDP {{ '2017-02-28T14:00:48+0000' | timeago}} • Webcast

$ENDP, which divested its Belbuca business and restructured Pain franchise business in 4Q16, announced its plans to divest Litha Healthcare Group business for $100MM to Acino. The company has also identified Somar business as non-core and will be conducting due diligence on divesting Somar to focus on regulated markets in developed countries.

$ENDP {{ '2017-02-28T12:57:20+0000' | timeago}} • Announcement

For FY17, $ENDP expects total revenues to be in the range of $3.45-3.60Bil and diluted EPS from continuing operations to be between $0.04-0.34. The company anticipates adjusted diluted EPS from continuing operations to be between $3.45-3.75.

$ENDP {{ '2017-02-28T12:53:37+0000' | timeago}} • Announcement

During 4Q16, $ENDP's U.S. Generic Pharmaceuticals business unit revenue rose 45% to $882MM, due to launch of quetiapine extended-release tablets. Revenues of U.S. Branded Pharmaceuticals fell 24% to $289MM. International pharmaceuticals revenue fell 18% to $70MM.

$ENDP {{ '2017-02-28T12:48:50+0000' | timeago}} • Announcement

Pharmaceutical company $ENDP reported net loss of $3.33Bil, or $14.98 per share, compared to $118MM, or $0.53 per share during 4Q15. Total revenues rose 16% YoY to $1.24Bil, helped by launch of generic products. Excluding items, $ENDP earned $1.77 per share.

Recent Transcripts

IMUC (ImmunoCellular Therapeutics, Ltd.)
Tuesday, November 21 2017 - 10:00pm
INFU (InfuSystem Holdings, Inc.)
Friday, November 10 2017 - 4:00pm
ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
NAVB (Navidea Biopharmaceuticals, Inc)
Wednesday, November 8 2017 - 1:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
NKTR (Nektar Therapeutics)
Tuesday, November 7 2017 - 10:00pm
MNK (Mallinckrodt Public Limited Company)
Tuesday, November 7 2017 - 1:30pm
DRRX (DURECT Corporation)
Wednesday, November 1 2017 - 8:30pm
STE (Steris Plc)
Wednesday, November 1 2017 - 2:00pm
MRK (Merck & Co. Inc.)
Friday, October 27 2017 - 12:00pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm
ALKS (Alkermes plc)
Thursday, October 26 2017 - 12:30pm
AMGN (Amgen Inc)
Wednesday, October 25 2017 - 9:00pm
BIIB (Biogen Inc.)
Tuesday, October 24 2017 - 12:30pm
ISRG (Intuitive Surgical, Inc.)
Thursday, October 19 2017 - 8:30pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
IMUC (ImmunoCellular Therapeutics, Ltd.)
Wednesday, August 23 2017 - 9:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm

AlphaGraphics you may like